Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Revenue of Prothena Corporation plc (PRTA)
Revenue in 2023 (TTM): $91.37 M
According to Prothena Corporation plc's latest financial reports the company's current revenue (TTM) is $91.37 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Prothena Corporation plc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $91.37 M | $-129,201,000 | $-190,108,000 | $-160,480,000 | $-147,028,000 |
| 2022 | $53.91 M | $47.16 M | $-131,557,000 | $-125,605,000 | $-116,949,000 |
| 2021 | $200.58 M | $118.29 M | $71.98 M | $71.92 M | $66.98 M |
| 2020 | $853 K | $-74,031,000 | $-111,220,000 | $-111,427,000 | $-111,144,000 |
| 2019 | $814 K | $-50,022,000 | $-78,938,000 | $-77,298,000 | $-77,677,000 |
| 2018 | $955 K | $-100,228,000 | $-152,899,000 | $-156,115,000 | $-155,645,000 |
| 2017 | $27.52 M | $-107,028,000 | $-152,187,000 | $-157,603,000 | $-153,237,000 |
| 2016 | $1.06 M | $-118,479,000 | $-156,537,000 | $-158,964,000 | $-160,108,000 |
| 2015 | $1.61 M | $-56,832,000 | $-79,131,000 | $-79,911,000 | $-80,612,000 |
| 2014 | $50.85 M | $12.4 M | $-5,906,000 | $-6,339,000 | $-7,150,000 |
| 2013 | $676 K | $-25,376,000 | $-39,767,000 | $-40,581,000 | $-40,996,000 |
| 2012 | $2.66 M | $-31,481,000 | $-40,942,000 | $-41,405,000 | $-41,411,000 |
| 2011 | $507 K | $507 K | $-28,853,000 | $-29,244,000 | $-29,670,000 |
| 2010 | $1.24 M | $1.24 M | $-11,971,000 | $-12,162,000 | $-12,482,000 |